Get started
Author

Sasha Amdur

Observed name: S. Amdur
Observed institution: Eli Lilly (United States)
OpenAlex ID: A5117581649
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy
2026 · Kevin Kalinsky, Seth A. Wander, et al. · Annals of Oncology
Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups
2026 · J. Cortes, S.R.D. Johnston, et al. · ESMO Open
PDF
PO 73 Efficacy And Safety Of Pirtobrutinib in Adults with Immune Thrombocytopenia: A Phase 1/2 Dose-Finding Study in Progress
2026 · Tomás José González-López, Catherine Broome, et al. · Research and Practice in Thrombosis and Haemostasis
Abstract PS1-08-08: monarchE: subgroup analysis of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer by nodal status
2026 · J. Cortes, S. R. D. Johnston, et al. · Clinical Cancer Research
The safety and efficacy of pirtobrutinib in adults with immune thrombocytopenia: A phase 1/2 dose-finding study in progress
2025 · Catherine Broome, Tomas Jose Gonzalez-Lopez, et al. · Blood
6MO Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients
2025 · S. Wander, E.P. Hamilton, et al. · ESMO Open
Works count: 5
Citation count:
H-index:
I10-index:
Year
Topic
Type